Vyriad
Dr Alice Bexon has over 20 years of experience in the pharmaceutical and medical device industries. Dr Alice began their career in 1997 as a Clinical Trial Manager at NDDO, followed by a role as a CRA at Parexel International (Paris). In 1998, they transitioned to a Medical Director role at sanofi-synthelabo, and then to an IML & CSL role at Roche in 2001. In 2007, they moved to Idera Pharmaceuticals as VP of Clinical Development. From 2012 to 2016, they held the role of CEO and Commercial Lead at Limmedx LLC, and then transitioned to a Clinical Lead role at eCTD Submit in 2014. In 2016, they moved to Vyriad as Chief Medical Officer, and then to Bexon Clinical Consulting, LLC as CEO and Principal Consultant in 2010. Dr Alice currently holds the position of CMO at Sapience Therapeutics, Inc. since 2019.
Dr Alice Bexon obtained their mbchb degree from the University of Bristol between 1989 and 1994, studying medicine. Dr Alice then attended Institut Gustave Roussy between 1995 and 1997, where they earned their Diploma in Oncology & chemotherapy.
This person is not in any offices
Vyriad
Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.